Catalysts About Xbrane Biopharma Xbrane Biopharma develops and co develops biosimilar drugs, with current programs focused on ophthalmology and immuno oncology. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Xbrane Biopharma Xbrane Biopharma develops and co-develops biosimilar medicines, with a current focus on ophthalmology and oncology products. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About Xbrane Biopharma Xbrane Biopharma develops and commercializes biosimilar medicines, with a focus on ophthalmology and oncology products in partnership driven models. What are the underlying business or industry changes driving this perspective?Read more
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults; and XB003, a biosimilar candidate to certolizumab pegol for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease and axial spondylitis. It also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma; and BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
